摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氯-6,7-二氢-5H-环戊并[4,5]噻吩并[2,3-D]嘧啶 | 300816-22-2

中文名称
4-氯-6,7-二氢-5H-环戊并[4,5]噻吩并[2,3-D]嘧啶
中文别名
4-氯-6,7-二氢-5H-环戊烷[4,5]噻吩[2,3-D]嘧啶
英文名称
4-chloro-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidine
英文别名
12-chloro-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9,11-tetraene
4-氯-6,7-二氢-5H-环戊并[4,5]噻吩并[2,3-D]嘧啶化学式
CAS
300816-22-2
化学式
C9H7ClN2S
mdl
MFCD00572400
分子量
210.687
InChiKey
JKXJMJPJOYMQSK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    108 °C
  • 沸点:
    355.6±37.0 °C(Predicted)
  • 密度:
    1.499±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    54
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 储存条件:
    室温

SDS

SDS:8852977e5a162ea90df81c7ad36a64fb
查看
Name: 4-Chloro-6 7-dihydro-5H-cyclopenta[4 5]thieno[2 3-d]pyrimidine Material Safety Data Sheet
Synonym: None Known
CAS: 300816-22-2
Section 1 - Chemical Product MSDS Name:4-Chloro-6 7-dihydro-5H-cyclopenta[4 5]thieno[2 3-d]pyrimidine Material Safety Data Sheet
Synonym:None Known

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
300816-22-2 4-Chloro-6,7-dihydro-5H-cyclopenta[4,5 97+ unlisted
Hazard Symbols: XI
Risk Phrases: 36/37/38

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 300816-22-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 108-109.5 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7ClN2S
Molecular Weight: 210.69

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Oxidizing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide, chlorine.
Hazardous Polymerization: Has not been reported.

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 300816-22-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Chloro-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidine - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 300816-22-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 300816-22-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 300816-22-2 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

  • 作为反应物:
    描述:
    4-氯-6,7-二氢-5H-环戊并[4,5]噻吩并[2,3-D]嘧啶溶剂黄146 三乙胺 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 反应 4.5h, 生成 (1r,4r)-N1-(6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-N4-methyl-N4-(3-phenylpropyl)cyclohexane-1,4-diamine
    参考文献:
    名称:
    [EN] IRAK INHIBITORS AND USES THEREOF
    [FR] INHIBITEURS D'IRAK ET LEURS UTILISATION
    摘要:
    本发明涉及化合物和方法,用于抑制一个或多个白细胞介素-1受体相关激酶("IRAK")。在某些实施例中,所提供的化合物抑制IRAK-1和IRAK-4。该发明还提供了包括本发明化合物的药学上可接受的组合物,以及使用所述组合物治疗各种疾病的方法。
    公开号:
    WO2012097013A1
  • 作为产物:
    参考文献:
    名称:
    Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines
    摘要:
    Pancreatic cancer is one of the most challenging diseases with seven months only as median survival time due to its poor prognosis. Several enzymes are blamed for the progress of pancreatic cancer especially, platelet-derived growth factor receptors (PDGFRs) this in turn makes them promising targets for its treatment. In this study, twenty eight new compounds based on thieno[2,3-d]pyrimidine scaffold were synthesized as anti-pancreatic cancer agents mimicking the benzofuro[3,2-d]pyrimidine derivative, amuvatinib. Various linkers including amides, esters, ketones, urea and thiourea derivatives were utilized to study their effect on the anti-proliferative activity of these compounds. Most of the tested compounds revealed good cytotoxic activities against pancreatic carcinoma cell line PANG-1. Compound 9d showed the highest cytotoxicity with an IC50 value of 5.4 mu M. Furthermore, 9d showed excellent platelet derived growth factor receptor (PDGFR-alpha) inhibitory activity, with IC50 value 0.155 mu M. Docking study was carried out into PDGFR-alpha active site which showed comparable binding mode to that of FDA approved PDGFR-alpha inhibitor, imatinib. 3D-Quantitative structure activity relationship (QSAR) model was built up with five-featured pharmacophore which could be implemented for emerging effective lead structures. These compounds could serve as a new chemotype for discovering new agents for pancreatic cancer therapy.
    DOI:
    10.1016/j.bioorg.2019.103472
点击查看最新优质反应信息

文献信息

  • Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists
    作者:Pingyuan Wang、Daniel E. Felsing、Haiying Chen、Sweta R. Raval、John A. Allen、Jia Zhou
    DOI:10.1021/acsmedchemlett.9b00050
    日期:2019.5.9
    recruitment in HEK293 cells. Here, we report the chemical synthesis, pharmacological evaluation, and molecular docking studies leading to the identification of two novel noncatechol D1R agonists that are a subnanomolar potent unbiased ligand 19 (PW0441) and a nanomolar potent complete G protein biased ligand 24 (PW0464), respectively. These novel D1R agonists provide important tools to study D1R activation and
    非儿茶酚杂环化合物最近被发现是具有优越药代动力学特性的强效和选择性 G 蛋白偏向多巴胺 1 受体 (D1R) 激动剂。为了确定以 G 蛋白或 β-arrestin 信号偏倚为中心的构效关系,围绕先导化合物 5 (PF2334) 的三个芳香药效团采用了系统的药物化学,生成了一系列新分子,这些分子在 D1R Gs- HEK293 细胞中依赖 cAMP 信号传导和 β-抑制蛋白募集。在这里,我们报告了化学合成、药理学评估和分子对接研究,这些研究导致了两种新型非儿茶酚 D1R 激动剂的鉴定,它们是亚纳摩尔强效无偏配体 19 (PW0441) 和纳摩尔强效完全 G 蛋白偏向配体 24 (PW0464),分别。
  • Discovery of novel akt1 inhibitor induces autophagy associated death in hepatocellular carcinoma cells
    作者:Meng Yu、Minghui Zeng、Zhaoping Pan、Fengbo Wu、Li Guo、Gu He
    DOI:10.1016/j.ejmech.2020.112076
    日期:2020.3
    derivatives were designed, synthesized and evaluated as novel AKT1 inhibitors. In vitro antitumor assay results showed that compounds 9d-g and 9i potently suppressed the enzymatic activities of AKT1 and potently inhibited the proliferation of HepG2, Hep3B, Huh-7 and SMMC-7721 cancer cell lines. Among these derivatives, the compound 9f demonstrated the best inhibitory activities on AKT1 (IC50 = 0.034 μM)
    在这项研究中,设计,合成和评估了一系列噻吩并[2,3-d]嘧啶衍生物,并将其作为新型AKT1抑制剂进行了评估。体外抗肿瘤测定结果表明,化合物9d-g和9i有效抑制AKT1的酶活性,并有效抑制HepG2,Hep3B,Huh-7和SMMC-7721癌细胞系的增殖。在这些衍生物中,化合物9f对AKT1(IC50 = 0.034μM)和Huh-7细胞(IC50 = 0.076μM)表现出最佳的抑制活性。一组生物学实验表明,化合物9f通过Akt / mTOR信号通路介导的自噬机制抑制了Huh-7的细胞增殖。此外,在皮下Huh-7异种移植模型中验证了9f的抗肿瘤能力。一起,
  • AlCl3-induced (hetero)arylation of thienopyrimidine ring: a new synthesis of 4-substituted thieno[2,3-d]pyrimidines
    作者:K. Shiva Kumar、Srinivas Chamakuri、Peddy Vishweshwar、Javed Iqbal、Manojit Pal
    DOI:10.1016/j.tetlet.2010.04.057
    日期:2010.6
    AlCl3 facilitated C–C bond forming reaction between 4-chloro-thieno[2,3-d]pyrimidines and (hetero)arenes affording a direct and single-step method for the synthesis of 4-(hetero)aryl substituted thieno[2,3-d]pyrimidines. A number of novel thienopyrimidines were prepared in good to excellent yields using this methodology. The molecular structure of a representative compound was established unambiguously
    AlCl 3促进4-氯-噻吩并[2,3- d ]嘧啶与(杂)芳烃之间的CC键形成反应,为合成4-(杂)芳基取代的噻吩并[2]提供了直接而又一步的方法。 ,3- d ]嘧啶。使用这种方法可以制备许多新颖的噻吩并嘧啶,收率良好。通过单晶X射线衍射明确地建立了代表性化合物的分子结构。
  • Convenient and Efficient Synthesis of Some Novel Fused Thieno Pyrimidines Using Gewald's Reaction
    作者:Ramakrishna V. S. Nirogi、Rama Sastri Kambhampati、Prabhakar Kothmirkar、Sobhanadri Arepalli、Narasimha Reddy G. Pamuleti、Anil K. Shinde、P. K. Dubey
    DOI:10.1080/00397911.2010.515357
    日期:2011.10
    Abstract Several functionalized thienopyrimidines were synthesized by a facile synthetic method, which includes Gewald's reaction, and were characterized by spectral and analytical data. These functionalized thienopyrimidines were converted to various new chemical entities of biological importance, such as 2-piperazinymethyl thienopyrimidines (6, 8), 4-dimethylaminoethoxy thienopyrimidines (11), and
    摘要 通过Gewald反应等简便的合成方法合成了几种功能化的噻吩并嘧啶,并通过光谱和分析数据进行了表征。这些功能化的噻吩并嘧啶被转化为各种具有生物学重要性的新化学实体,例如 2-哌嗪甲基噻吩并嘧啶 (6, 8)、4-二甲氨基乙氧基噻吩并嘧啶 (11) 和 3-二甲氨基乙基噻吩并嘧啶 (12)。筛选由此合成的所有化合物的体外生物活性。一些化合物显示出有希望的血清素 5-HT6 受体拮抗剂活性。
  • Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication
    作者:Marcella Bassetto、Pieter Leyssen、Johan Neyts、Mark M. Yerukhimovich、David N. Frick、Andrea Brancale
    DOI:10.1016/j.ejmech.2016.07.035
    日期:2016.11
    technique was applied to the study of the HCV NS3 helicase, with the aim to find novel inhibitors of the HCV replication. A library of approximately 450000 commercially available compounds was analysed in silico and 21 structures were selected for biological evaluation in the HCV replicon assay. One hit characterized by a substituted thieno-pyrimidine scaffold was found to inhibit the viral replication with
    基于结构的虚拟筛选技术已应用于HCV NS3解旋酶的研究,目的是寻找HCV复制的新型抑制剂。在计算机上分析了大约450000种可商购化合物的文库,并选择了21种结构用于HCV复制子测定的生物学评估。发现一个以取代的噻吩并嘧啶骨架为特征的命中物以亚微摩尔范围的EC 50值和良好的选择性指数抑制病毒复制。设计并合成了不同系列的新型噻吩并嘧啶衍生物。几个新结构显示出在低或亚微摩尔范围内的抗病毒活性。
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇 7-溴噻吩并[3,2-d]嘧啶 7-溴噻吩并[3,2-D]嘧啶-4(1H)-酮 7-溴-噻吩并[3,2-d]嘧啶-4-胺 7-溴-4-氯噻酚并[3,2-D]嘧啶 7-溴-2-氯噻吩并[3,2-D]嘧啶